Medication info
Jadiwon Tablet 25 Milligrams (Empagliflozin)

Jadiwon Tablet 25 Milligrams (Empagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tablet
Manufacturer / importer
Genupharm Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
PTP - 10 tablets/PTP [(10 tablets/PTP×1)], PTP - 30 tablets/PTP [(10 tablets/PTP×3)]
Approval status
Active

MFDS item code 202105611 · Approved 2021.07.29 · Insurance code 698004770

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine for monotherapy and as add-on combination therapy with other glucose-lowering agents, including insulin, is 10 mg once daily. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken regardless of food. Swallow the tablet whole. If a dose is missed, take it as soon as remembered. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Do not initiate treatment with this medicine in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose of this medicine at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those undergoing dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as they have not been studied. •Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions)

Ingredients

Manufacturer
Genupharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication is used to assist in blood sugar control in adult patients with type 2 diabetes. It can be administered alone or in combination with other medications along with dietary and exercise therapy. Caution is advised, especially in patients with cardiovascular disease whose blood sugar is not adequately controlled, and it is important to seek professional advice. This medication effectively improves patients' blood sugar levels and aids in diabetes management.

How to take

Adult dose

The recommended dose of this medicine for monotherapy and as add-on combination therapy with other glucose-lowering agents, including insulin, is 10 mg once daily. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken regardless of food. Swallow the tablet whole. If a dose is missed, take it as soon as remembered. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Do not initiate treatment with this medicine in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose of this medicine at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those undergoing dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as they have not been studied. •Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions)

Precautions

This medication should not be used in patients with allergic reactions to the active ingredient or other components. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication is not to be used in patients with significantly reduced kidney function, specifically those with a glomerular filtration rate (GFR) of less than 30 mL/min/1.73 m2, end-stage renal disease, or those undergoing dialysis. This medication contains lactose, so it should not be given to patients with genetic issues such as lactose intolerance, lactase deficiency, or glucose-galactose malabsorption. In patients with mildly impaired kidney function, this medication should be given cautiously with regular monitoring of kidney function. Especially when the GFR is less than 60 mL/min/1.73 m2, dose adjustment may be necessary, and if it is less than 45 mL/min/1.73 m2, this medication should be discontinued. In heart failure patients, it should be used cautiously in mild to moderate cases and is not recommended for severe heart failure patients. When used in conjunction with insulin or sulfonylureas, adjustments may be necessary to manage hypoglycemia risk. During treatment with this medication, adverse reactions such as hypoglycemia, infections, particularly genital infections, increased urination, urinary tract infections, and decreased fluid volume may occur. Rarely, serious metabolic acidosis called ketoacidosis may occur, and immediate treatment should be sought if symptoms appear. Caution is needed for the elderly or those at high risk of fluid loss, as this medication may lower blood pressure or lead to dehydration. There is also a risk of serious infections such as urosepsis, pyelonephritis, and genital fungal infections, so symptoms should be monitored, and treatment administered if necessary. This medication may show a positive reaction in urine glucose tests, so caution should be taken in interpreting test results. Care is needed when driving or operating machinery due to the risk of hypoglycemia, especially when used in combination with insulin. Its use is not recommended during pregnancy, and administration should be discontinued once pregnancy is confirmed. If breastfeeding, it is advisable to discontinue nursing since this medication may be excreted in breast milk. Safety and efficacy have not been established in patients under 18 years of age, so it is not used in this population. In overdose situations, appropriate treatment should be provided based on the patient's condition, and methods to remove this medication via dialysis are not known. This medication should be kept out of the reach of children and should not be transferred to other containers.

Side effects

  • Hypoglycemia
  • ketoacidosis
  • vulvovaginitis
  • balanitis
  • other genital infections
  • urinary tract infection
  • perineal necrosis
  • pruritus
  • rash
  • urticaria
Show 12 more
  • angioedema
  • decreased fluid volume
  • increased urination
  • urinary retention
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased blood creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urosepsis
  • pyelonephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1°C and 30°C at room temperature to preserve its effectiveness and safety for a longer period.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

PTP - 10 tablets/PTP [(10 tablets/PTP×1)], PTP - 30 tablets/PTP [(10 tablets/PTP×3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.